[HTML][HTML] Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International journal of …, 2013 - Elsevier
Background Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International …, 2013 - portalrecerca.uab.cat
Background Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
FS Gutzwiller, AM Pfeil, J Comin-Colet, P Ponikowski… - 2013 - cabidigitallibrary.org
Background: Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
FS Gutzwiller, AM Pfeil, J Comin-Colet… - … Journal of Cardiology, 2013 - europepmc.org
Background Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
[PDF][PDF] Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International Journal …, 2013 - scholar.archive.org
Florian S. Gutzwiller a,⁎, Alena M. Pfeil a, Josep Comin-Colet b, Piotr Ponikowski c, d,
Gerasimos Filippatos e, Claudio Mori f, Peter G. Braunhofer f, Thomas D. Szucs a, Matthias …
Gerasimos Filippatos e, Claudio Mori f, Peter G. Braunhofer f, Thomas D. Szucs a, Matthias …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International journal of …, 2013 - folia.unifr.ch
METHODS A randomised, double-blind, placebo-controlled trial (n= 459) in iron-deficient
chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL …
chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis
FS Gutzwiller, AM Pfeil, J Comin-Colet… - … journal of cardiology, 2013 - edoc.unibas.ch
Heart failure (HF) is a burden to patients and health care systems. The objectives of HF
treatment are to improve health related quality of life (HRQoL) and reduce mortality and …
treatment are to improve health related quality of life (HRQoL) and reduce mortality and …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International journal of …, 2013 - sonar.ch
METHODS A randomised, double-blind, placebo-controlled trial (n= 459) in iron-deficient
chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL …
chronic heart failure (CHF) patients with or without anaemia studied clinical and HRQoL …
Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis
FS Gutzwiller, AM Pfeil, J Comin-Colet, P Ponikowski… - 2013 - pubmed.ncbi.nlm.nih.gov
Background Heart failure (HF) is a burden to patients and health care systems. The
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
objectives of HF treatment are to improve health related quality of life (HRQoL) and reduce …
[PDF][PDF] Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose
FS Gutzwiller, AM Pfeil, J Comin-Colet… - International Journal of …, 2013 - core.ac.uk
Florian S. Gutzwiller a,⁎, Alena M. Pfeil a, Josep Comin-Colet b, Piotr Ponikowski c, d,
Gerasimos Filippatos e, Claudio Mori f, Peter G. Braunhofer f, Thomas D. Szucs a, Matthias …
Gerasimos Filippatos e, Claudio Mori f, Peter G. Braunhofer f, Thomas D. Szucs a, Matthias …